A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).

被引：9
|
作者：
Rossi, Jean-Francois
Moreaux, Jerome
Rose, Mikaelle
Picard, Marie
Ythier, Arnaud
Rossier, Ciara
Sievers, Eric
Klein, Bernard
机构：
[1] Univ Hosp, Unit Cellular & Gene Therapy, Montpellier, France
[2] Serono Int, Geneva, Switzerland
[3] Zymogenet Inc, Seattle, WA 98105 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3578.3578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3578
引用
收藏
页码：1022A / 1022A
页数：1
相关论文
共 50 条
  • [41] A phase II trial of sorafenib in patients with relapsing and resistant multiple myeloma (MM) previously treated with bortezomib (S0434)
    Srkalovic, G.
    Hussein, M.
    Bolejack, V.
    Hoering, A.
    Zonder, J.
    Barlogie, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [42] Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Ogawa, Yoshiaki
    Tobinai, Kensei
    Ogura, Michinori
    Ando, Kiyoshi
    Tsuchiya, Takahide
    Kobayashi, Yukio
    Watanabe, Takashi
    Maruyama, Dai
    Morishima, Yasuo
    Kagami, Yoshitoyo
    Taji, Hirofumi
    Minami, Hironobu
    Itoh, Kuniaki
    Nakata, Masanobu
    Hotta, Tomomitsu
    CANCER SCIENCE, 2008, 99 (01): : 140 - 144
  • [43] A phase I/II study of Pomalidomide, Ixazomib, Clarithromycin and Dexamethasone (PICd) in patients with relapsed or refractory Multiple Myeloma (RRMM)
    Rosenberg, Aaron
    Munoz, Meilen
    Costello, Caitlin
    Brem, Elizabeth
    Reid, Erin
    Maverakis, Emanual
    Kaesberg, Paul
    Lee, Lisa
    Abedi, Mehrdad
    Tuscano, Joseph
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S157 - S158
  • [44] A Phase I/II Study of Pomalidomide-Cyclophosphamide-Prednisone (PCP) in Patients with Multiple Myeloma Relapsed/Refractory to Lenalidomide
    Palumbo, Antonio
    Larocca, Alessandra
    Carella, Angelo Michele
    Rossi, Davide
    Montefusco, Vittorio
    Ferrari, Samantha
    Santagostino, Alberto
    Guglielmelli, Tommasina
    Galli, Monica
    Capaldi, Antonio
    Giuliani, Nicola
    La Verde, Giacinto
    Omede, Paola
    Baldi, Ileana
    Boccadoro, Mario
    Corradini, Paolo
    BLOOD, 2011, 118 (21) : 289 - 290
  • [45] A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma.
    Gasparetto, Cristina
    Green, Michael
    Srinivasan, Anandgopal
    Kang, Yubin
    Rizzieri, David A.
    Decastro, Carlos
    Diehl, Louis F.
    Beaven, Anne
    Li, Zighuo
    Rao, Arati V.
    Garrett, Anderson
    Tuchman, Sascha
    Long, Gwynn D.
    BLOOD, 2015, 126 (23)
  • [46] A multicenter phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (Dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM).
    Richardson, Paul
    Lonial, S.
    Jakubowiak, A.
    Wolf, J.
    Krishnan, A.
    Densmore, J.
    Singhal, S.
    Ghobrial, I.
    Schwartzberg, L.
    Colson, K.
    Harris, J.
    Kendall, T.
    Martineau, I.
    Obadike, N.
    Sullivan, K.
    Pearson, S.
    Hideshima, T.
    Lai, L.
    Sportelli, P.
    Gardner, L.
    Birch, R.
    Henderson, I. C.
    Anderson, K. C.
    BLOOD, 2006, 108 (11) : 1023A - 1023A
  • [47] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma (MM-014 phase 2 trial): a subanalysis of patients previously treated with lenalidomide and a proteasome inhibitor
    Bahlis, Nizar J.
    Schiller, Gary J.
    Sebag, Michael
    Berdeja, Jesus G.
    Ganguly, Siddhartha
    Matous, Jeffrey V.
    Song, Kevin
    Seet, Christopher
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand M.
    Fonseca, Gustavo
    Reece, Donna E.
    Vogel, Prisca
    Lee, Kim
    Chung, Weiyuan
    Agarwal, Amit
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S141 - S141
  • [48] A phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease
    Berenson, J. R.
    Yellin, O.
    Mapes, R.
    Eades, B.
    Abaya, C. D.
    Strayer, A.
    Nix, D.
    Swift, R. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Bendamustine, Bortezomib and Dexamethasone (BVD) in Patients with Relapsed-Refractory Multiple Myeloma (MM): Updated Results of a Multicenter Phase II Study
    Offidani, Massimo
    Maracci, Laura
    Corvatta, Laura
    Marina, Liberati Anna
    Ballanti, Stelvio
    Attolico, Imma
    Caraffa, Patrizia
    Alesiani, Francesco
    di Toritto, Tommaso Caravita
    Gentili, Silvia
    Tosi, Patrizia
    Brunori, Marino
    Derudas, Daniele
    Ledda, Antonio
    Gozzetti, Alessandro
    Cellini, Claudia
    Malerba, Lara
    Mele, Anna
    Felici, Stefano
    Galimberti, Sara
    Mondello, Patrizia
    Pulini, Stefano
    Coppetelli, Ugo
    Fraticelli, Paolo
    Rizzi, Rita
    Leoni, Pietro
    BLOOD, 2014, 124 (21)
  • [50] Phase II study evaluating the efficacy and safety of CNTO328 in combination with dexamethasone for patients with relapsed/refractory multiple myeloma (MM)
    Voorhees, P. M.
    Manges, R. F.
    Sonneveld, P.
    Somlo, G.
    Jagannath, S.
    Zweegman, S.
    Munteanu, M.
    Vermeulen, J. T.
    Xie, H.
    Orlowski, R. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345